Recuro’s At-Home & Onsite COVID Testing Solution Can Ensure Workplace Safety as Delta Variant Cases Grow 

The Centers for Disease Control and Prevention (CDC) estimates that the Delta variant represents about 99% of new COVID-19 infections. As a result, there is a sharp, increased demand for COVID At-Home or Onsite Testing solutions. Employers recognize that frequent or ongoing testing can ensure a safe return-to-work and employee participation at crucial meetings, events and conventions.

An avalanche of requests from employers has continued for Recuro’s at-home and onsite COVID testing solutions in the last few weeks. The Recuro solution ensures workplace safety while testing and monitoring employees for COVID-19 and provides employees with a convenient, accessible and confidential at-home and worksite lab testing experience.

CDC Guidelines for Workplace-Based Testing

The CDC offers guidelines for workplace-based testing for SARS-CoV2, the virus that causes COVID, that could identify workers with COVID infection and help either prevent or reduce transmission. There are different screening tests (testing asymptomatic workers with no known or suspected exposure to COVID) or antigen tests for serial screening testing for high-density critical infrastructure sectors. These are workers who are together for the same period for 8-12 hours per shift and have prolonged close contact within 6 feet for 15 minutes or more.

When COVID-19 is identified in the workplace, the CDC recommends a testing strategy for reducing transmission of the virus. Performing screening for COVID symptoms, testing and contact tracing are key to identifying those exposed to prevent disease transmission and possible outbreaks.

Testing for the Delta Variant Requires Recuro’s Precise Solution  

Recuro offers a testing platform designed to personalize the at-home testing experience with customized self-collection testing services including COVID-19 PCR and antigen rapid tests. Chosen from a field of hundreds of companies as one of 12 to collaborate directly with the US Department of Health and Human Services and the FDA during the pandemic and credited with launching one of the first comprehensive employer testing platforms for COVID-19.

The Recuro Health Testing Solution includes all supplies and management software needed: shallow nose swab PCR and rapid testing kits. The solution embodies an integrated, structured process for test distribution and administration, validation of results and back-end reporting.

The Recuro testing solution supports employers with key decision-making responsibilities satisfying OSHA requirements for employees’ safe return-to-work as well as safe participation in crucial meetings, events and convention safety.

These real-time test results are available to authorized stakeholders, oversight from nationwide physicians, unique, customized employer dashboards and tools available to make a reopening strategy easily managed and documented. Proprietary software makes the full beginning-to-end testing journey simple, safe, customized and compliant.

For more information about how to ensure workplace safety, go to www.recurohealth.com/covid-back-to-work.

 

 

 

default-image3

Recuro Health Supports SIIA Annual Meeting: Provides Voluntary COVID-19 Antigen Rapid Testing for Attendees, CEO Michael Gorton Panel Presenter

DALLAS—(BUSINESS WIRE)—Recuro Health(Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes...